<?xml version="1.0"?>
<trials subjects="1">
  <Triall>
    <main>
      <UTRN />
      <trial_id>ChiCTR-OIN-17010831</trial_id>
      <utrn />
      <reg_name>ChiCTR</reg_name>
      <date_registration>2017-03-10</date_registration>
      <primary_sponsor>Hengxiang Wang</primary_sponsor>
      <public_title>A pilot study of recombinant human thrombopoietin in enhancing hematopoietic stem cell homing and engraftment after transplantation</public_title>
      <acronym />
      <scientific_title>A pilot study of recombinant human thrombopoietin in enhancing hematopoietic stem cell homing and engraftment after transplantation</scientific_title>
      <Scientific_acronym />
      <date_enrolment>2014-03-01</date_enrolment>
      <type_enrolment />
      <target_size>recombinant human TPO group:60;Control group:60;</target_size>
      <recruitment_status>Recruiting</recruitment_status>
      <url>http://www.chictr.org.cn/showproj.aspx?proj=17169</url>
      <study_type>Observational study</study_type>
      <study_design>Non randomized control</study_design>
      <phase>I+II (Phase I+Phase II)</phase>
      <hc_freetext>Hematologic diseases </hc_freetext>
      <i_freetext>recombinant human TPO group:subcutaneously injection of recombinant human TPO;Control group:no injection with recombinant human TPO;</i_freetext>
      <results_actual_enrolment />
      <results_date_completed />
      <results_url_link />
      <results_summary />
      <results_date_posted />
      <results_date_first_publication />
      <results_baseline_char />
      <results_participant_flow />
      <results_adverse_events />
      <results_outcome_measures />
      <results_url_protocol />
      <results_IPD_plan />
      <results_IPD_description />
    </main>
    <contacts>
      <contact>
        <type>Scientific</type>
        <firstname>Yanhua LI</firstname>
        <middlename />
        <lastname />
        <address>27 Taiping Road, Haidian District, Beijing, China</address>
        <city />
        <country1 />
        <zip />
        <telephone>+86 010 66931947</telephone>
        <email>shirlylyh@126.com</email>
        <affiliation>Academy of Military Medical Sciences</affiliation>
      </contact>
      <contact>
        <type>Public</type>
        <firstname>Xuetao Pei</firstname>
        <middlename />
        <lastname />
        <address>27 Taiping Road, Haidian District, Beijing, China</address>
        <city />
        <country1 />
        <zip />
        <telephone>+86 010 66931947</telephone>
        <email>shirlylyh@126.com</email>
        <affiliation>Academy of Military Medical Sciences</affiliation>
      </contact>
    </contacts>
    <countries>
      <country2>China</country2>
    </countries>
    <criteria>
      <inclusion_criteria>1) Hematopoietic diseases:: acute myeloid leukemia, acute lymphoblastic leukemia, severe aplastic anemia, myelodysplastic syndrome;
2) Ages 11-55, males and females;
3) Complete remission before transplantation and without CNS or extramedullary infiltration;
4) Voluntary written informed consent;
5) No completely HLA-identical donors;
6) No sever function diseases in heart, brain, lung, liver or kidney or other organs.
7) Volunteers can be followed up for the treatment effect after transplantation.</inclusion_criteria>
      <agemin>11</agemin>
      <agemax>55</agemax>
      <gender>Both</gender>
      <exclusion_criteria>1) No voluntary written informed consent or relatives' informed consent;
2) Ages under 11, and above 55;
3) Uncomplete remission before transplantation, with CNS or extramedullary infiltration;
4) Severe function disorder in major organs, or with tumor or severe infection diseases;
5) Not suitable for Haplo-HSCT.</exclusion_criteria>
    </criteria>
    <health_condition_code>
      <hc_code />
    </health_condition_code>
    <health_condition_keyword>
      <hc_keyword />
    </health_condition_keyword>
    <intervention_code>
      <i_code>;;</i_code>
    </intervention_code>
    <intervention_keyword>
      <i_keyword />
    </intervention_keyword>
    <primary_outcome>
      <prim_outcome>neutrophil  engraftment;platelet   engraftment;platelet   Recovery;</prim_outcome>
    </primary_outcome>
    <secondary_outcome>
      <sec_outcome>aGVHD;</sec_outcome>
    </secondary_outcome>
    <secondary_sponsor>
      <sponsor_name />
    </secondary_sponsor>
    <secondary_ids>
      <secondary_id>
        <sec_id />
        <issuing_authority />
      </secondary_id>
    </secondary_ids>
    <source_support>
      <source_name>self-paying</source_name>
    </source_support>
    <ethics_reviews>
      <ethics_review>
        <status>Approved</status>
        <approval_date>2016-12-18</approval_date>
        <contact_name />
        <contact_address />
        <contact_phone />
        <contact_email />
      </ethics_review>
    </ethics_reviews>
  </Triall>
</trials>